Aspirus Heart and Vascular Institute-Research and Education Report issue

Academic/Hospital Phase 3

Organization Overview

First Clinical Trial
2009
NCT00998218
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2009

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 3 Trials (3)

furosemide (lasix) (1 trial)

ranolazine (ranexa) (1 trial)

sodium chloride (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Death (Phase 3)

Death, Sudden, Cardiac (Phase 3)

Heart Failure (Phase 3)

Renal Insufficiency (Phase 3)

Ventricular Dysfunction (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 2
  • # of Trial APIs: 3